Lilly Strikes Deal for Orna Therapeutics for Up to $2.4 Billion

Eli Lilly & Co agreed to buy US biotech Orna Therapeutics Inc. for up $2.4 billion in cash in the latest deal by the company best known for its weight-loss...

By Deirdre Hipwell · Bloomberg Markets

Eli Lilly & Co agreed to buy US biotech Orna Therapeutics Inc. for up $2.4 billion in cash in the latest deal by the company best known for its weight-loss drug Zepbound.